Skip to main content

Therapeutic application of adipose-derived stromal vascular fraction in diabetic foot

Abstract

Diabetic foot is one of the severest complications of diabetes. In severe cases, this disease may be lead to amputation or even death due to secondary infection and ischemic necrosis. Since the ineffectiveness of traditional therapy, autologous stem cell transplantation has been used to treat diabetic foot. This simple, safe, and effective therapy is expected to be applied and promoted in the future.

In this review, we described the detailed pathogenesis of diabetic foot and the common clinical treatments currently used. We also revealed vascular remodeling as the potential mechanism of therapeutic functions of adipose-derived stromal vascular fraction (SVF) in treating diabetic foot.

Background

Recently, the incidence of diabetes is increasing in the world, and the age of onset has decreased year by year. Diabetes has become a health problem that cannot be ignored and the prolonged presence of hyperglycemia could induce various complications including diabetic foot [1].

Diabetic foot is caused by diseases of peripheral blood vessels at different degrees and abnormalities of the distal lower limb nerves in diabetic patients, resulting in foot infections, ulcers, and deep tissue damage [2]. Peripheral vascular disease of diabetes often involves the lower extremity arteries. At the early stage, it is mainly characterized by intermittent claudication. As the arterial stenosis increases, the patients could have rest pain or even could not walk. Later, the ischemia with infection and neuropathy could cause local tissue necrosis, ulcers, and gangrene, leading to ischemic diabetic foot [3]. Finally, 10% of patients’ toes have to be amputated, and the serious infection caused by diabetic foot might even threaten their lives [4]. It has been reported that infection is the main cause of disability and death in diabetic foot patients, while neurogenic and ischemic infections account for 45 ~ 60%, of which 25 ~ 44% are caused by the neuropathy, and 10% are caused by blood-lacking [5]. This disease affects the patients’ life quality and brings a heavy economic burden to their families.

Since the pathological process of diabetic foot is extremely complicated, traditional medical therapy, vascular bypass, interventional surgery, and amputation treatment methods have certain limitations [6]. Stem cell transplantation technology for the treatment of diabetic foot is a hotspot of transplanted angiogenesis in recent years. Stem cells have the characteristics of high self-renewal, proliferation, and multiple differentiation potential, as well as paracrine effects, which promote the regeneration of blood vessels and nerve tissues around the transplant site so that the affected ulcers could achieve blood circulation reconstruction and blood supply improvement and, eventually, achieve the purpose of healing diabetic foot [7,8,9].

The stromal vascular fraction is an active component in adipose tissue and contains a variety of cells including adipose stem cells [10]. Since the various cell types, they have strong regenerative potentials such as angiogenesis, tissue remodeling, and immune regulation. It has been used for clinic treatment of various conditions and shown good safety and healing effects. Moon and colleagues injected SVF cells into the affected area of diabetic foot patients, and the microvascular blood flow of the wound surface was found significantly increased with no adverse reactions [11, 12]. Studies found that SVF could secrete a variety of cytokines, differentiate into various cells such as endothelial cells, and have the potential to participate in angiogenesis in vivo. Therefore, it can improve local blood circulation and form the microenvironment that is conducive to tissue cell survival and functional maintenance [13,14,15].

Pathogenesis of diabetic foot

Diabetic foot caused by neuropathy

The most common complication of diabetes is diabetic neuropathy, accounting for 30% to 50% of diabetic patients. The incidence is similar for men and women, but men usually occur earlier than women as their lifestyle and testosterone deficiency [16]. The symptoms of diabetic neuropathy include central neuropathy and peripheral neuropathy, resulting in sensory, motor, and autonomic neuropathy. The pathogenesis of the disease may be related to the increase of neurotrophic factors and the decrease or disappearance of protective factors [17]. Sensory neuropathy is an important cause of diabetic foot. It often involves the small nerves that innervate the pain and temperature of the foot, which leads to a decrease in the sensitivity of the patient to stress-related trauma and skin damage. Therefore, the self-protection mechanism is lost, and the harmful stimulation cannot be sensed in time so that the foot is vulnerable to injury [18]. Motor neuropathy mainly affects small peripheral nerves, which lead to abnormal innervation of the gastrocnemius muscle group (mainly flexor) in feet. This imbalance in innervation will cause a change in the shape of the foot, causing the humeral head to protrude. Meanwhile, under the friction of improper footwear and gravity distribution, it is easy to cause foot damage, which leads to foot deformity and ulcer [19]. Autonomic neuropathy is the most complicated in the diabetic neuropathy, which could involve all organs and systems of the whole body. After the occurrence of autonomic neuropathy, the ability of autonomic regulation of skin blood flow is lost. At the same time, the arteriovenous short circuit and shunt increase. Although the skin temperature is not low and the color is pink, the nutritional blood supply has decreased [20]. Also, autonomic neuropathy could cause a lack of secretion of sweat and lipid glands, which makes the skin dry, prone to chapped, and become the gateway to bacterial invasion, eventually leading to ulcers [21].

Diabetic foot caused by vascular lesion

Diabetes can cause a wide range of vascular diseases, involving arteries, veins, and capillaries. Vascular disease leads to the decrease or even occlusion of blood flow in lower limbs, which becomes the pathological basis of diabetic foot [22]. The major vascular disease caused by diabetes is mainly atherosclerosis. The main causes may include hyperlipidemia, hyperglycemia, carbon monoxide reduction, insulin resistance, hemagglutination abnormalities, changes in blood flow, etc. [23]. When atherosclerosis occurs in diabetic patients, the plaque contains more calcium, the expression of inflammatory markers increases, and it affects the blood vessels in the more distal part, especially the foot. It is more difficult to form the collateral circulation after vascular occlusion [24]. The risk of diabetic foot ulcer increased significantly after diabetic peripheral arterial disease, and often asymptomatic until the ulcer occurred. Besides, the reduction of blood supply is not only conducive to wound healing and response to infection, but also more likely to make foot lesions [25].

The microvascular complications of diabetes are mainly microcirculatory disorders, including microvascular disease, microvascular disorder, and changes in blood physicochemical properties. In the pathogenesis of diabetic foot, these three interact with each other and cause each other [26]. Diabetes may cause changes in microvascular function, oxygen partial pressure, and vascular permeability, as well as disturbance of rhythmic contraction of arterioles and arterioles. These abnormalities can cause a decrease in capillary blood flow in the skin and an increase in vascular permeability and platelet aggregation, which leads to the thickening of vascular endothelial cells and aggravation of microvascular disease. After a long time, it could cause vascular stenosis, insufficient perfusion of tissues and organs, and blood circulation disorder at the distal end of the limb, which eventually leads to the occurrence of diabetic foot [27].

Diabetic foot caused by infection

If peripheral neuropathy and vascular lesion are indispensable conditions for the development of the diabetic foot, infection is the direct reason for diabetic foot [28]. The abnormal immune response of diabetic patients leads to the impairment of the phagocytic capacity of neutrophils, which weakens their response to infection or injury. At the same time, ischemia will further aggravate this response [5]. Foot infection generally could be attributed to four independent risk factors: deep trauma, recurrent trauma, long-lasting trauma (> 30 days), and peripheral vascular disease [29]. About one-third of diabetic patients develop a fever when they have a foot infection, but the number of white blood cells may not increase despite widespread infection. However, if the patient has sensory neuropathy, the perception of pain or temperature is weakened, so the perception of infection will be delayed [30]. If the patient’s blood sugar cannot be controlled, the infection will be difficult to control. Also, the blood circulation disorder will eventually lead to the rapid deterioration of the wound [31] (Table 1).

Table 1 Pathology of diabetic foot and the main citation

Current therapy for diabetic foot

Current treatment for diabetic foot includes drug therapy, vascular intervention therapy, dressing adjuvant therapy, hyperbaric oxygen therapy, vacuum suction therapy, growth factor therapy, and stem cell therapy [32].

However, none of the above are sufficient for treating diabetic foot. Drugs used in diabetic foot are mainly for vascular diseases, neuropathy, and hypoglycemic drugs [33]. Drug therapy for patients with mild and moderate diabetic feet simply delays the development of their lesions; it is the basis for the treatment of diabetic foot. Once the drug therapy is not effective and the ischemia is getting serious, the vascular intervention surgery needs to be used to reconstruct the blood flow [34]. However, since most of the diabetics are old and frail, who often suffer from cardiovascular and cerebrovascular diseases, thus, the patients cannot tolerate the stimulation of surgical bypass. Besides, the vascular lesions involve many small arteries and segments, which leads to the lack of distal artery outflow channel in some patients, and thus, the vascular bypass graft and interventional treatment are not applicable [35]. Meanwhile, long-term follow-up showed that patients with diabetic foot were prone to restenosis after vascular intervention. The proportion of patients who opt for amputation remains high [6].

Also, non-surgical therapies include dressing adjuvant therapy, hyperbaric oxygen therapy, and vacuum suction therapy. This kind of simple physical auxiliary intervention could improve the wound inflammation and microcirculation, which promote wound healing, but the treatment requires long-term hospitalization while the effect is not that significant [36]. Cytokine treatment to promote wound healing is a new method for diabetic foot. The cytokines used mainly include fibroblast growth factor (FGF), epidermal growth factor (EGF), platelet growth factor (PGF), vascular endothelial cell growth factor (VEGF), cell colony-stimulating factor(G-CSF), and hepatocyte growth factor (HGF) [37].

In recent years, stem cell transplantation has been considering a cutting-edge technology to treat diabetic foot. Although stem cells are not currently used as a routine means for treating diabetic foot in clinical practice, many researchers have reported that stem cell transplantation could promote neovascularization of ischemic limbs, improve and restore limb blood flow, and ultimately cure the diabetic foot [38,39,40,41].

Therapy for diabetic foot with stem cells

Stem cells are a class of cells with self-renewal and multi-directional differentiation potential that can differentiate into specific types of cells under specific conditions [42]. Stem cell transplantation for the treatment of diabetic foot is mainly based on the principle that stem cells can differentiate into vascular endothelial cells and smooth muscle cells in vivo, secreting numerous pro-angiogenic factors to form new blood vessels. The stem cells are transplanted into the ischemic lower limbs to gradually differentiate and form new capillaries, which improves and restores blood flow to the lower limbs, and achieves the purpose of treating diabetic foot [43].

Currently, the stem cells used to treat diabetic foot are derived from many tissue sources such as the bone marrow, umbilical cord, placenta, cord blood, heart, liver, spleen, pulp, dermis, and adipose tissue. Among them, adipose-derived stem cells are advantageous of the widely distributed but low immunogenicity adipose tissue, which is easier to obtain but less harmful to patients [44]. Many initial studies were adipose-derived stem/stromal cells (ASCs) identified by Zuk, which have received extensive attention due to their pluripotent differentiation potential, paracrine properties, and significant influence on regenerative medicine [45]. ASCs are a group of homogeneous stem cells obtained by the adherent subculture of freshly isolated SVF. SVF is a heterogeneous cell population obtained by digesting adipose tissue [46]. However, compared to ASCs, SVF does not require any cell culture process and can be used directly after separation. Therefore, it is relatively safer and can meet lower regulatory standards, which is favored by many clinical researchers [47].

SVF is widely used to improve diabetic foot [48]. Tan’s research found that SVF can increase the viability and migration of fibroblasts in a hyperglycemic environment by upregulating cytokines around the wound, thereby accelerating wound healing [49]. Chae used SVF to treat diabetic foot and found that not only the number of fibroblasts increased significantly, but also the amount of collagen synthesized by fibroblasts increased significantly. The results of subsequent clinical experiments showed that when 100% of the wounds of patients treated with SVF were healed, the healing rate of the control group was only 62%, indicating that SVF could accelerate wound healing [50] (Table 2).

Table 2 Diabetic foot treatment and the therapy features

SVF cells for diabetic foot

Acquisition of SVF cells

The adipose tissue in the human body is generally divided into subcutaneous fat and visceral fat, which can be obtained by liposuction or surgical resection. Common materials include abdomen, buttocks, forearms, groin, etc. [51]. In general, the separation methods of SVF could be generally divided into two categories: enzymatic methods that use proteolytic enzymes to digest adipose tissue and physical and mechanical processing methods that do not use proteolytic enzymes [52]. Enzymatic methods often use type I collagenase to digest adipose tissue. The general process is summarized as follows: the adipose tissue and collagenase are mixed at an appropriate ratio and placed in a 37 °C environment for 1 h with shaking and digestion; then an equal amount of complete medium is added to terminate the digestion. The supernatant is discarded by centrifugation, then washed with phosphate buffer saline (PBS), and finally, filtered through a specific pore size filter to obtain an SVF suspension. Physical and mechanical digestion of adipose tissue, including methods such as serum digestion, mechanical shaking, and bolus shearing. Compared to enzymatic methods, this kind of digestion method takes more time, and the cell yield and activity are not good enough; thus, it is not widely used [53].

Cell populations in SVF

Human adipose tissue can be easily obtained from the abdomen, buttocks, forearm, or groin liposuction or surgical resection. SVF cells could be obtained after adipose tissue is digested with proteolytic enzymes [54]. SVF cells isolated from the adipose tissue are heterogeneous cell populations containing a variety of cells. This multicellular component could be identified by different cell surface molecules. Surface molecules of cells, the cluster of differentiation (CD), could be used to identify different cell types in a cell population [55]. The International Cell Therapy Association has stated to define SVF using this identification method. At present, the academic community has reached a consensus on the cell types contained in SVF cells [56]. SVF cells contain a variety of cell types, such as ASCs; hematopoietic stem cells (HPCs), mesenchymal cells; and endothelial progenitor cells (EPCs), endothelial cells, pericytes, and macrophages [57,58,59].

Application of SVF in diabetic foot

SVF cells are able to promote the recovery of the diabetic foot through various effects. SVF, for instance, contains various cells which directly or indirectly secrete bioactive factors to induce degradation of the basement membrane, affecting the proliferation and migration of endothelial cells, thereby promoting the fusion and remodeling of new blood vessels. Also, these cytokines could increase the stability of the pericytes to the vascular network [13, 49, 60].

Differentiation of SVF

Among SVF cells, ASCs not only occupy a relatively large amount of cells but also have strong differentiation ability. ASCs are pluripotent stem cells that could differentiate directly into vascular endothelial cells, smooth muscle cells, and pericytes. These cells regulate vascular growth, stabilization, and maturation through activation of TGF-β, angiopoietin-2, PDGF-B/PDGFR-β, Notch, and S1P/Edg signaling pathways [61, 62]. Meanwhile, pericytes not only promote the appearance of endothelial progenitor cells but also maintain vascular integrity to form a vascular network [63]. Studies have shown that ASCs could also participate in the formation of new micro-vessel together with endothelial cells to form a stable vascular network system [64]. Animal experiments have demonstrated that transplanted ASCs could differentiate into endothelial cells, significantly improving blood flow and capillary density in diabetic and non-diabetic animal models of lower limb ischemia [65].

Paracrine action of SVF

Studies have found that when SVF cells are transplanted into the ischemic area, their vascular density, blood flow, and secreted hepatocyte growth factor, vascular endothelial growth factor, and basic fibroblast growth factor (bFGF) are significantly increased compared with the control group [66]. If the synthesis of HGF is inhibited, the ability of SVF cells to promote vascularization of ischemic tissue is significantly reduced [67]. Stem cells treated with VEGF antibodies also lose pro-angiogenic capacity in ischemic tissues [68].

ASCs in SVF cells could effectively secrete a large number of pro-angiogenic and anti-apoptotic factors, such as HGF, bFGF, VEGF, PGF-B, and TGF-β [69]. Prochzka isolated the factors secreted by ASCs and injected them into the ischemic limbs of rabbits. It was found that the blood perfusion of ischemic tissue in the experimental group was twice as high as that in the control group. Immunohistochemistry showed that the capillary density of the experimental group was significantly higher than the control group, which indicates ASC-secreted cytokines could promote angiogenesis [70].

In addition to ASCs, other components in SVF cells can also promote vascular remodeling through the paracrine pathway. Studies have shown that hypoxia can induce macrophages to secrete vascular regenerative factors such as VEGF and bFGF, thereby promoting the formation of new blood vessels [71]. Macrophages in adipose tissues can be divided into M1 type macrophages and M2 type macrophages according to their activation states. In SVF cells, more than 90% of macrophages are M2 type [72]. M2 type macrophage is an anti-inflammatory macrophage. It can secrete anti-inflammatory factors such as IL-4, IL-10, TGF-β, and pro-angiogenic factors such as bFGF and VEGF, thereby inhibiting the inflammatory response and promoting vascular network formation [73].

Endothelial cells secrete exosomes, and adjacent endothelial cells can act as target cells to bind to exosomes, promoting endothelial growth, migration, and neovascularization [74]. Endothelial cells can activate the ERK1/2 signaling pathway by expressing CXCL-1, induce the secretion of epidermal growth factor, and promote angiogenesis [75]. Besides, stromal cells, fibroblasts, and smooth muscle cells can secrete HGF and regulate angiogenesis [76].

Mechanism of cytokine promoting vascular reconstruction

SVF cell components or hypoxic tissue can secrete a large amount of cytokines through paracrine, and these active substances can accelerate the healing of diabetic foot by promoting the biological function of the body cells [69,70,71]. For instance, VEGF could activate endothelial progenitor cells and induce endothelial cells to secrete a variety of cathepsins for degradation of extracellular matrix, as well as inhibit endothelial cell apoptosis and promote endothelial cell proliferation, migration, and neovascularization [77]. HGF binds to its receptor and promotes the proliferation of vascular endothelial cells by activating the Grb2/Sos-Ras-Raf-MAPK signaling pathway [76]. bFGF induces VEGF expression via the FGFR1/c-Src/p38/NFB-κB signaling pathway [78]. At the same time, the activation of NFB-κB can promote endothelial cell DNA synthesis, cell division, and cell proliferation and promote the regeneration of blood vessels [79]. TGF-β contributes to the production of extracellular matrix and promotes the interaction between endothelial cells and parietal cells, which in turn contributes to the formation of blood vessels [80] (Table 3).

Table 3 SVF cells for diabetic foot and its pros and cons

Conclusion and prospect

As a new therapy for the treatment of diabetic foot, autologous adipose-derived stem cell transplantation has been widely used in clinical practice and has made it possible to exempt some patients from amputation or reduce the amputation plane and improve the quality of life, which fully demonstrates the feasibility of this technology [15, 81]. SVF is a heterogeneous cell population, which interact with each other to synergize with the whole process of the angiogenesis. However, the specific mechanism of synergistic angiogenesis and reconstruction between components still needs further investigation. Although SVF cells have achieved good therapeutic effects in many studies, further research is still needed to determine whether the cell therapy has side effects such as transplant toxicity and adverse reactions in the long-term treatment. The evaluation of the effect of SVF cells on the treatment of diabetic foot, including the survival of stem cells, the rate of proliferation and transformation, and the determination of the characteristics of transformed cells, still needs to be studied and solved in the future study.

In general, although using SVF cells to treat diabetic foot is still in the early research stage, it has enormous potential in clinical application. It is believed that with further investigation, adipose-derived SVF cells will ultimately show their unique cellular advantages and therapeutic value in clinic.

Availability of data and materials

Not applicable

Abbreviations

SVF:

Stromal vascular fraction

FGF:

Fibroblast growth factor

EGF:

Epidermal growth factor

PGF:

Platelet growth factor

VEGF:

Vascular endothelial cell growth factor

G-CSF:

Granulocyte colony-stimulating factor

HGF:

Hepatocyte growth factor

ASCs:

Adipose-derived stem/stromal cells

PBS:

Phosphate buffer saline

CD:

Cluster of differentiation

HPCs:

Hematopoietic stem cells

EPCs:

Endothelial progenitor cells

bFGF:

Basic fibroblast growth factor

References

  1. 1.

    Weck M, Slesaczeck T, Rietzsch H, et al. Noninvasive management of the diabetic foot with critical limb ischemia: current options and future perspectives. Ther Adv Endocrinol Metab. 2011;2(6):247–55.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Apelqvist J, Bakker K, Van Houtum W, et al. International consensus and practical guidelines on the management and the prevention of the diabetic foot. Diabetes Metab Res Rev. 2000;16(S1):84–92.

    Google Scholar 

  3. 3.

    Park JY, Jung HG. Diabetic foot: ulcer, infection, ischemic gangrene. Foot and ankle disorders. Springer. Ther Adv Endocrinol Metab. 2016;24(02):555–84.

  4. 4.

    Rahelić D. Of IDF diabetes atlas--call for immediate action. Lijec Vjesn. 2016;138(1–2):57–8.

    PubMed  Google Scholar 

  5. 5.

    Shearman CP, Windhaber RJS. Foot complications in patients with diabetes. Surgery (Oxford). 2010;28(6):288–92.

    Google Scholar 

  6. 6.

    Vouillarmet J, Bourron O, Gaudric J, et al. Lower-extremity arterial revascularization: is there any evidence for diabetic foot ulcer-healing? Diabetes Metab. 2016;42(1):4–15.

    CAS  PubMed  Google Scholar 

  7. 7.

    Blumberg SN, Berger A, Hwang L, et al. The role of stem cells in the treatment of diabetic foot ulcers. Diabetes Res Clin Pract. 2012;96(1):1–9.

    PubMed  Google Scholar 

  8. 8.

    Lopes L, Setia O, Aurshina A, et al. Stem cell therapy for diabetic foot ulcers: a review of preclinical and clinical research. Stem Cell Res Ther. 2018;9(1):188.

    PubMed  PubMed Central  Google Scholar 

  9. 9.

    Zarei F, Negahdari B, Eatemadi A, et al. Diabetic ulcer regeneration: stem cells, biomaterials, growth factors. Artif Cells Nanomed Biotechnol. 2018;46(1):26–32.

    PubMed  Google Scholar 

  10. 10.

    Han S, Sun HM, Hwang KC, et al. Adipose-derived stromal vascular fraction cells: update on clinical utility and efficacy. Crit Rev Eukaryot Gene Expr. 2015;25(2):145–52.

    PubMed  Google Scholar 

  11. 11.

    Zanata F, Shaik S, Devireddy R V, et al. Cryopreserved adipose tissue-derived stromal/stem cells: potential for applications in clinic and therapy. Biobanking and Cryopreservation of Stem Cells. Springer. Adv Exp Med Biol. 2016;951(01):137–46.

  12. 12.

    Moon KC, Chung HY, Han SK, et al. Possibility of injecting adipose-derived stromal vascular fraction cells to accelerate microcirculation in ischemic diabetic feet: a pilot study. Int J Stem Cells. 2019;12(1):107–13.

    PubMed  PubMed Central  Google Scholar 

  13. 13.

    Didangelos T, Koliakos G, Kouzi K, et al. Accelerated healing of a diabetic foot ulcer using autologous stromal vascular fraction suspended in platelet-rich plasma. Regen Med. 2018;13(3):277–81.

    CAS  PubMed  Google Scholar 

  14. 14.

    Lonardi R, Leone N, Gennai S, et al. Autologous micro-fragmented adipose tissue for the treatment of diabetic foot minor amputations: a randomized controlled single-center clinical trial (MiFrAADiF). Stem Cell Res Ther. 2019;10(1):223.

    PubMed  PubMed Central  Google Scholar 

  15. 15.

    Andia I, Maffulli N, Burgos AN. Stromal vascular fraction technologies and clinical applications. Expert Opin Biol Ther. 2019;19(12):1289–05.

    PubMed  Google Scholar 

  16. 16.

    Pafili K, Papanas N, Ziegler D. Neuropathy in diabetes:“one cannot begin it too soon”. Angiology. 2018;69(9):752–4.

    PubMed  Google Scholar 

  17. 17.

    Jaiswal M, Divers J, Urbina E, et al. Cardiovascular autonomic neuropathy in adolescents and young adults with type 1 and type 2 diabetes: the SEARCH for diabetes in youth cohort study. Pediatr Diabetes. 2018;19(4):680–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Kalish J, Hamdan A. Management of diabetic foot problems. Int J Surg. 2010;51(2):476–86.

    Google Scholar 

  19. 19.

    Papanas N, Maltezos E. The diabetic foot: a global threat and a huge challenge for Greece. Hippokratia. 2009;13(4):199–04.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Vinik AI, Casellini C, Parson HK, et al. Cardiac autonomic neuropathy in diabetes: a predictor of cardiometabolic events. Front Neurosci. 2018;12:591.

    PubMed  PubMed Central  Google Scholar 

  21. 21.

    Andrews KL, Dyck PJ, Kavros SJ, et al. Plantar ulcers and neuropathic arthropathies: associated diseases, polyneuropathy correlates, and risk covariates. Adv Skin Wound Care. 2019;32(4):168–75.

    PubMed  Google Scholar 

  22. 22.

    Troisi N, Ercolini L, Chisci E, et al. Diabetic foot infection: preliminary results of a fast-track program with early endovascular revascularization and local surgical treatment. Ann Vasc Surg. 2016;30:286–91.

    PubMed  Google Scholar 

  23. 23.

    Green E, Johnson B. Evaluation and management of vascular disease in the diabetic patient. The Surgical Management of the Diabetic Foot and Ankle. Springer. 2016. p. 19–27. https://doi.org/10.1007/978-3-319-27623-6_3.

  24. 24.

    Ferik S, Güven H, Ateş MP, et al. Diabetic polyneuropathy, deep white matter lesions, and carotid atherosclerosis: is there any association? Neurol Sci. 2018;39(1):103–10.

    PubMed  Google Scholar 

  25. 25.

    Malyar NM, Freisinger E, Meyborg M, et al. Amputations and mortality in in-hospital treated patients with peripheral artery disease and diabetic foot syndrome. J Diabetes Complicat. 2016;30(6):1117–22.

    PubMed  Google Scholar 

  26. 26.

    Dioszegi A, Vass M, Nemeth N, et al. Rheopheresis treatment of diabetic foot syndrome. Atherosclerosis. 2017;263:e272.

    Google Scholar 

  27. 27.

    American Diabetes Association. Microvascular complications and foot care: standards of medical care in diabetes 2018. Diabetes Care. 2018;41(1):S105–18.

    Google Scholar 

  28. 28.

    Lavery LA, Ryan EC, Ahn J, Crisologo PA, Oz OK, La Fontaine J, Wukich DK. The Infected Diabetic Foot: Reevaluating the Infectious Diseases Society of America Diabetic Foot Infection Classification. Clin Infect Dis. 2020;70(8):1573–9. https://doi.org/10.1093/cid/ciz489.

  29. 29.

    Lavery LA, Armstrong DG, Wunderlich RP, et al. Risk factors for foot infections in individuals with diabetes. Diabetes Care. 2006;29(6):1288–93.

    PubMed  Google Scholar 

  30. 30.

    Markakis K, Faris A, Sharaf H, et al. Local antibiotic delivery systems: current and future applications for diabetic foot infections. Int J Low Extrem Wounds. 2018;17(1):14–21.

    CAS  PubMed  Google Scholar 

  31. 31.

    Eltzschig H, Eckle T. Ischemia and reperfusion—from mechanism to translation. Nat Med. 2011;17(11):1391–01.

    CAS  PubMed  Google Scholar 

  32. 32.

    Lipsky BA. Diabetic foot infections: current treatment and delaying the post antibiotic era. Diabetes Metab Res Rev. 2016;32:246–53.

    PubMed  Google Scholar 

  33. 33.

    Karri V, Kuppusamy G, Talluri SV, et al. Current and emerging therapies in the management of diabetic foot ulcers. Curr Med Res Opin. 2016;32(3):519–42.

    CAS  PubMed  Google Scholar 

  34. 34.

    Ibrahim A, Practice C. IDF clinical practice recommendation on the diabetic foot: a guide for healthcare professionals. Diabetes Res Clin Pract. 2017;127:285–7.

    PubMed  Google Scholar 

  35. 35.

    Joret M, Dean A, Cao C, et al. The financial burden of surgical and endovascular treatment of diabetic foot wounds. J Vasc Surg. 2016;64(3):648–55.

    PubMed  Google Scholar 

  36. 36.

    Mutluoglu M, Lipsky B. Non-surgical treatment of diabetic foot osteomyelitis. Lancet Diabetes Endocrinol. 2017;5(8):668.

    PubMed  Google Scholar 

  37. 37.

    Rivero-González A, Martín-Izquierdo E, Marín-Delgado C, et al. Cytokines in diabetes and diabetic complications. Cytokine Effector Functions in Tissues. Elsevier. Academic Press; 2017. p. 119–28. https://doi.org/10.1016/B978-0-12-804214-4.00006-3.

  38. 38.

    Cao Y, Gang X, Sun C, et al. Mesenchymal stem cells improve healing of diabetic foot ulcer. J Diabetes Res. 2017;2017:9328–47.

    Google Scholar 

  39. 39.

    Mizukami H, Yagihashi S. Is stem cell transplantation ready for prime time in diabetic polyneuropathy? Curr Diab Rep. 2016;16(9):86.

    PubMed  Google Scholar 

  40. 40.

    Qin H, Zhu X, Zhang B, et al. Clinical evaluation of human umbilical cord mesenchymal stem cell transplantation after angioplasty for diabetic foot. Exp Clin Endocrinol Diabetes. 2016;124(08):497–03.

    CAS  PubMed  Google Scholar 

  41. 41.

    Wu Q, Lei X, Chen L, et al. Autologous platelet-rich gel combined with in vitro amplification of bone marrow mesenchymal stem cell transplantation to treat the diabetic foot ulcer: a case report. Ann Transl Med. 2018;6(15):307.

    PubMed  PubMed Central  Google Scholar 

  42. 42.

    Gehling UM, Ergün S, Schumacher U, et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood. 2000;95(10):3106–12.

    CAS  PubMed  Google Scholar 

  43. 43.

    Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002;360(9331):427–35.

    PubMed  Google Scholar 

  44. 44.

    Tobita M, Orbay H, Mizuno H. Adipose-derived stem cells: current findings and future perspectives. Discov Med. 2011;11(57):160–70.

    PubMed  Google Scholar 

  45. 45.

    Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7(2):211–28.

    CAS  PubMed  Google Scholar 

  46. 46.

    Locke M, Windsor J, Dunbar P. Human adipose-derived stem cells: isolation, characterization and applications in surgery. ANZ J Surg. 2009;79(4):235–44.

    PubMed  Google Scholar 

  47. 47.

    Domergue S, Bony C, Maumus M, et al. Comparison between stromal vascular fraction and adipose mesenchymal stem cells in remodeling hypertrophic scars. PLoS One. 2016;11(5):e0156161.

    PubMed  PubMed Central  Google Scholar 

  48. 48.

    Haney N, Gabrielson A, Kohn T, et al. The use of stromal vascular fraction in the treatment of male sexual dysfunction: a review of preclinical and clinical studies. Sex Med Rev. 2019;7(2):313–20.

    PubMed  Google Scholar 

  49. 49.

    Tan S, Yeo X, Liang Z, et al. Stromal vascular fraction promotes fibroblast migration and cellular viability in a hyperglycemic microenvironment through up-regulation of wound healing cytokines. Exp Mol Pathol. 2018;104(3):250–5.

    CAS  PubMed  Google Scholar 

  50. 50.

    Chae DS, Han S, Son M, et al. Stromal vascular fraction shows robust wound healing through high chemotactic and epithelialization property. Cytotherapy. 2017;19(4):543–54.

    CAS  PubMed  Google Scholar 

  51. 51.

    Piché ME, Vasan SK, Hodson L, et al. Relevance of human fat distribution on lipid and lipoprotein metabolism and cardiovascular disease risk. Curr Opin Lipidol. 2018;29(4):285–92.

    PubMed  Google Scholar 

  52. 52.

    Shani N, Gur E, Solodeev I, et al. Mechanical apparatus and method for isolating stromal vascular fraction: U.S. Patent Application. 2018;15:579–02.

    Google Scholar 

  53. 53.

    Van D, Tuin A, Spiekman M, et al. Comparison of intraoperative procedures for isolation of clinical grade stromal vascular fraction for regenerative purposes: a systematic review. J Tissue Eng Regen Med. 2018;12(1):e261–74.

    Google Scholar 

  54. 54.

    Bourin P, Bunnell BA, Casteilla L, et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy. 2013;15(6):641–8.

    PubMed  PubMed Central  Google Scholar 

  55. 55.

    Michelle L, John W, Rod D. Human adipose-derived stem cells: isolation, characterization and applications in surgery. ANZ J Surg. 2010;79(4):235–44.

    Google Scholar 

  56. 56.

    Nguyen A, Guo J, Banyard D, et al. Stromal vascular fraction: a regenerative reality? Part 1: current concepts and review of the literature. J Plast Reconstr Aesthet Surg. 2016;69(2):170–9.

    PubMed  Google Scholar 

  57. 57.

    Guo J, Nguyen A, Banyard D, et al. Stromal vascular fraction: a regenerative reality? Part 2: mechanisms of regenerative action. J Plast Reconstr Aesthet Surg. 2016;69(2):180–8.

    PubMed  Google Scholar 

  58. 58.

    Bora P, Majumdar AS. Adipose tissue-derived stromal vascular fraction in regenerative medicine: a brief review on biology and translation. Stem Cell Res Ther. 2017;8(1):145.

    PubMed  PubMed Central  Google Scholar 

  59. 59.

    Gentile P, Orlandi A, Scioli MG, et al. Concise review: adipose-derived stromal vascular fraction cells and platelet-rich plasma: basic and clinical implications for tissue engineering therapies in regenerative surgery. Stem Cells Transl Med. 2012;1(3):230–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  60. 60.

    Gadelkarim M, Abushouk AI, Ghanem E, et al. Adipose-derived stem cells: effectiveness and advances in delivery in diabetic wound healing. Biomed Pharmacother. 2018;107:625–33.

    CAS  PubMed  Google Scholar 

  61. 61.

    Maumus M, Peyrafitte J, D'angelo R, et al. Native human adipose stromal cells: localization, morphology and phenotype. Int J Obes. 2011;35(9):1141–53.

    CAS  Google Scholar 

  62. 62.

    Gimble J, Katz A, Bunnell B. Adipose-derived stem cells for regenerative medicine. Circ Res. 2007;100(9):1249–60.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. 63.

    Mills J, Cowin AJ, Kaur PJC. Pericytes, mesenchymal stem cells and the wound healing process. Cells. 2013;2(3):621–34.

    CAS  PubMed  PubMed Central  Google Scholar 

  64. 64.

    Paquet J, Moya A, Bensidhoum M, et al. Engineered cell-free scaffold with two-stage delivery of miRNA-26a for bone repair. Ann Transl Med. 2016;4(10):204.

    PubMed  PubMed Central  Google Scholar 

  65. 65.

    Miranville A, Heeschen C, Sengenes C, et al. Improvement of postnatal neovascularization by human adipose tissue-derived stem cells. Circulation. 2004;110(3):349–55.

    CAS  PubMed  Google Scholar 

  66. 66.

    Atalay S, Coruh A, Deniz KJ. Stromal vascular fraction improves deep partial thickness burn wound healing. Burns. 2014;40(7):1375–83.

    PubMed  Google Scholar 

  67. 67.

    Cai L, Johnstone BH, Cook TG, et al. Suppression of hepatocyte growth factor production impairs the ability of adipose-derived stem cells to promote ischemic tissue revascularization. Stem Cells. 2007;25(12):3234–43.

    CAS  PubMed  Google Scholar 

  68. 68.

    Sasaki KI, Murohara T, Ikeda H, et al. Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. J Clin Invest. 2002;109(5):603–11.

    CAS  PubMed  PubMed Central  Google Scholar 

  69. 69.

    Kwon HM, Hur SM, Park KY, et al. Multiple paracrine factors secreted by mesenchymal stem cells contribute to angiogenesis. Vasc Pharmacol. 2014;63(1):19–28.

    CAS  Google Scholar 

  70. 70.

    Procházka V, Jurčíková J, Laššák O, et al. Therapeutic potential of adipose-derived therapeutic factor concentrate for treating critical limb ischemia. Cell Transplant. 2016;25(9):1623–33.

    PubMed  Google Scholar 

  71. 71.

    Nucera S, Biziato D, Palma M. The interplay between macrophages and angiogenesis in development, tissue injury and regeneration. Int J Dev Biol. 2011;55(4–5):495–03.

    CAS  PubMed  Google Scholar 

  72. 72.

    Eto H, Ishimine H, Kinoshita K, et al. Characterization of human adipose tissue-resident hematopoietic cell populations reveals a novel macrophage subpopulation with CD34 expression and mesenchymal multipotency. Stem Cells Dev. 2012;22(6):985–97.

    PubMed  PubMed Central  Google Scholar 

  73. 73.

    Li P, Lu M, Nguyen M, et al. Functional heterogeneity of CD11c-positive adipose tissue macrophages in diet-induced obese mice. J Biol Chem. 2010;285(20):15333–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  74. 74.

    Van B, De J, Smits M, et al. Endothelial cells require miR-214 to secrete exosomes that suppress senescence and induce angiogenesis in human and mouse endothelial cells. Blood. 2013;121(19):3997–06.

    Google Scholar 

  75. 75.

    Miyake M, Goodison S, Urquidi V, et al. Expression of CXCL1 in human endothelial cells induces angiogenesis through the CXCR2 receptor and the ERK1/2 and EGF pathways. Lab Investig. 2013;93(7):768–78.

    CAS  PubMed  Google Scholar 

  76. 76.

    Newman A, Chou W, Welch RK, et al. Analysis of stromal cell secretomes reveals a critical role for stromal cell–derived hepatocyte growth factor and fibronectin in angiogenesis. Arterioscler Thromb Vasc Biol. 2013;33(3):513–22.

    CAS  PubMed  PubMed Central  Google Scholar 

  77. 77.

    Hao C, Shintani S, Shimizu Y, et al. Therapeutic angiogenesis by autologous adipose-derived regenerative cells: comparison with bone marrow mononuclear cells. Am J Physiol Heart Circ Physiol. 2014;307(6):H869–H79.

    CAS  PubMed  Google Scholar 

  78. 78.

    Tzeng H, Chen P, Lin K, et al. Basic fibroblast growth factor induces VEGF expression in chondrosarcoma cells and subsequently promotes endothelial progenitor cell-primed angiogenesis. Clin Sci (Lond). 2015;129(2):147–58.

    CAS  Google Scholar 

  79. 79.

    Yi E, Kim Y. Xylitol inhibits in vitro and in vivo angiogenesis by suppressing the NF-κB and Akt signaling pathways. Int J Oncol. 2013;43(1):315–20.

    CAS  PubMed  Google Scholar 

  80. 80.

    Hirschi K, Skalak T, Peirce SM, et al. Vascular assembly in natural and engineered tissues. Ann N Y Acad Sci. 2002;961(1):223–42.

    CAS  PubMed  Google Scholar 

  81. 81.

    Eyuboglu A, Uysal C, Ozgun G, et al. The effect of adipose derived stromal vascular fraction on stasis zone in an experimental burn model. Burns. 2018;44(2):386–96.

    PubMed  Google Scholar 

Download references

Acknowledgements

Not applicable

Funding

There has been no significant financial support for this work that could have influenced its outcome.

Author information

Affiliations

Authors

Contributions

XZ was the major contributor in writing the manuscript. WH and LJ reviewed and revised the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Wenjun Hu or Han Yin or Liang Jin.

Ethics declarations

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

The authors declare no conflict of interest, financial or otherwise.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhao, X., Guo, J., Zhang, F. et al. Therapeutic application of adipose-derived stromal vascular fraction in diabetic foot. Stem Cell Res Ther 11, 394 (2020). https://doi.org/10.1186/s13287-020-01825-1

Download citation

Keywords

  • Diabetic foot
  • Stem cells therapy
  • Stromal vascular fraction (SVF)
  • Cytokine
  • Vascular reconstruction